Is There an Ozempic Pill? Oral Ozempic Tablets in the US, and What Canada Has Instead
The Ozempic pill is daily oral semaglutide for type 2 diabetes, launched in the US in 2026. Rybelsus link, side effects, weight loss and Canadian status.
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Short answer
Yes, in the United States. In January 2026 the FDA approved the name Ozempic tablets for a reformulated, smaller semaglutide tablet that was first approved in December 2024 as a new version of Rybelsus. It reached US pharmacies on May 4, 2026. It is the same molecule as the weekly Ozempic injection, taken as a tablet once a day, and it is approved for adults with type 2 diabetes: to lower blood sugar and to reduce the risk of heart attack, stroke and cardiovascular death in people at high risk. It is not approved for weight loss; the oral semaglutide approved for weight management is the Wegovy pill. In Canada there is no product called the Ozempic pill: the same reformulated tablet is sold under the Rybelsus name. Not medical advice. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance. Last reviewed November 1, 2026.
Ozempic pill vs the other semaglutide products
Sources: the US Rybelsus and Ozempic tablets label (revised January 2026) and Health Canada's Drug Product Database, checked November 1, 2026.
| Ozempic pill (US) | Ozempic injection | Rybelsus | Wegovy pill | |
|---|---|---|---|---|
| Form | Daily tablet | Weekly pen injection | Daily tablet | Daily tablet, higher strength |
| Approved for | Type 2 diabetes; cardiovascular risk reduction | Type 2 diabetes; cardiovascular and kidney risk reduction | Type 2 diabetes; cardiovascular risk reduction | Weight management; cardiovascular risk reduction (US) |
| Food and water rules | Empty stomach, a little plain water, wait before eating | None; any time of day | Same as the Ozempic pill | Same as the Ozempic pill |
| In Canada | Not sold under this name | Authorized | Authorized, including the reformulated tablet | Not authorized |
Is the Ozempic pill just Rybelsus renamed?
Mostly. Novo Nordisk reformulated the Rybelsus tablet so more semaglutide is absorbed from a smaller pill. The FDA approved that version on bioequivalence data and the original Rybelsus trials, then let it carry the Ozempic name so patients recognise it as semaglutide. Both now share one US label. The strength numbers printed on the two tablets are different and the label says they are not interchangeable number for number, so switching between them, or from the injection to a tablet, is a prescriber decision.
Like Rybelsus, the tablet contains an absorption enhancer called SNAC, because stomach acid and enzymes break down most of a swallowed peptide. That is why the label asks for an empty stomach in the morning, a small amount of plain water only, the tablet swallowed whole, and a wait of at least 30 minutes before food, drinks or other pills. More on how oral absorption works: oral semaglutide.
Side effects of the Ozempic pill
Any stomach or bowel side effect was reported by 32% and 41% of people on the two maintenance strengths vs 21% on placebo, mostly while the dose was being stepped up; 4% and 8% stopped because of them vs 1% on placebo. For comparison, nausea in the Ozempic injection trials was 16 to 20% vs 6% on placebo, so the pill is not gentler on the stomach. The label carries the same warnings as the injection: a boxed thyroid C-cell tumour warning from rodent studies, pancreatitis, gallbladder disease, low blood sugar when combined with insulin or a sulfonylurea, kidney injury from dehydration, diabetic eye complications and aspiration under anesthesia. See Ozempic side effects, nausea and Rybelsus side effects.
| Side effect (label, placebo-controlled trials) | Tablet, lower strength | Tablet, higher strength | Placebo |
|---|---|---|---|
| Nausea | 11% | 20% | 6% |
| Abdominal pain | 10% | 11% | 4% |
| Diarrhea | 9% | 10% | 4% |
| Decreased appetite | 6% | 9% | 1% |
| Vomiting | 6% | 8% | 3% |
| Constipation | 6% | 5% | 2% |
Does the Ozempic pill work for weight loss?
It is not approved for weight loss, and the diabetes trials showed modest weight change. In the label's 26-week placebo trial, average weight fell 3.7 kg on the higher tablet strength vs 1.4 kg on placebo. In the comparable 30-week trial of the Ozempic injection, weight fell 4.7 kg on the higher original strength vs 1.2 kg on placebo. These are separate trials, not a head-to-head comparison. The higher-strength Wegovy pill, tested for weight loss, averaged 13.6% vs 2.2% on placebo in OASIS 4. More: Ozempic for weight loss and Wegovy pill.
Heart protection: the SOUL trial
The pill's cardiovascular claim comes from SOUL (NEJM, 2025): 9,650 adults with type 2 diabetes and heart disease or chronic kidney disease, followed for about four years. Heart attack, stroke or cardiovascular death occurred in 12.0% on oral semaglutide vs 13.8% on placebo, a 14% relative reduction. The FDA added this use in October 2025 and Health Canada added it for Rybelsus in January 2026.
Is there an Ozempic pill in Canada?
No product is sold in Canada as the Ozempic pill. Health Canada's Drug Product Database lists Ozempic only as an injection. The reformulated semaglutide tablet sold in the US as the Ozempic pill is listed in Canada as Rybelsus, marketed since March 13, 2026, alongside the original Rybelsus tablets. The Wegovy pill had not been authorized in Canada as of November 1, 2026, and the generic semaglutide now in Canadian pharmacies is injectable only (see generic semaglutide in Canada).
Coverage: Ontario's Drug Benefit formulary added the reformulated Rybelsus tablets on March 31, 2026 as Limited Use benefits for type 2 diabetes when metformin is not enough or not suitable, and it will not fund oral and injectable semaglutide together. Nova Scotia lists Rybelsus as an exception-status drug; BC PharmaCare and New Brunswick do not list it. Neither form is covered by public plans for weight loss. Details by province: Ozempic coverage in Canada and Rybelsus in Canada.
What users report here
None of the confessions published as of November 1, 2026 mention Rybelsus or the Ozempic pill; semaglutide stories here are almost all about the weekly injections. Read them on the semaglutide hub and in the Semaglutide hub.
Related topics
data reports:
related peptides:
in Canada:
community guides:
More confessions from the archive
Community Q&A
- Is there an Ozempic pill?
- Yes, in the US. The FDA approved Ozempic tablets in January 2026 and they reached pharmacies on May 4, 2026. They are daily oral semaglutide for adults with type 2 diabetes.
- Is the Ozempic pill the same as Rybelsus?
- Same molecule. The Ozempic pill is a reformulated, smaller Rybelsus tablet that absorbs more efficiently, so its strength numbers differ. Both share one US label and are not interchangeable number for number.
- Is the Ozempic pill available in Canada?
- Not under that name. In Canada the same reformulated tablet is sold as Rybelsus, by prescription, for type 2 diabetes.
- Can you take the Ozempic pill for weight loss?
- It is approved for type 2 diabetes, not weight loss, and trial weight loss was modest. The oral semaglutide approved for weight management in the US is the Wegovy pill, which is not authorized in Canada.
- Is the Ozempic pill as effective as the injection?
- There is no head-to-head trial. In separate placebo trials, blood-sugar and weight changes were in a similar range, with slightly more weight loss on the injection. A prescriber can explain which form suits a person.
- What are the Ozempic pill's side effects?
- Mainly nausea (up to 20% vs 6% on placebo), stomach pain, diarrhea, less appetite, vomiting and constipation, mostly while the dose is being increased. It has the same serious warnings as the injection.
- Does this page give dosing advice?
- Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Sources
Last reviewed November 1, 2026. Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.